Years of medication development have resulted in treatments that ease the symptoms of schizophrenia, an illness that affects approximately 24 million people worldwide.
Psychosis is a symptom of schizophrenia, which is often associated with significant impairment and can impact all aspects of functioning in personal, familial, social, academic, and occupational spheres.
Antipsychotic pharmaceuticals, formerly major tranquilizers and neuroleptics, are the primary class of treatments for schizophrenia. Additionally, they treat those experiencing psychosis brought on by bipolar illness, depression, or Alzheimer's disease.
These medications are far from ideal, despite being used to treat individuals with schizophrenia or other illnesses pretty often. In a step toward this objective, researchers at Northwestern Medicine have built a new road for more potent medications for schizophrenia and produced findings that imply the mechanism of action of these medications is more complex than initially believed.
These scientists have transcended conventional approaches, which mainly depend on analyzing the effects of potential antipsychotic drugs on mouse behavior. The novel methodology of the current study may have incredible promise for forecasting the effectiveness of these medications in patients.
This assurance is derived from a significant antipsychotic medication discovery. These substances prevent the neurotransmitter dopamine from being produced, which is considered to be a factor in the symptoms of schizophrenia. According to the current study, antipsychotics reduce dopamine production by interacting with a different kind of brain cell than was previously believed.
According to the main researcher, Jones G. Parker of Northwestern University, this groundbreaking study rewrites the knowledge of the brain causes of psychosis and opens up new avenues for its future treatment. He goes on to say that it creates new opportunities for medicines with fewer adverse side effects than those seen today.
In the striatum, a part of the brain, cells create the chemical dopamine. The striatum contains two types of neuronal cells: those with D1 and those with D2 dopamine receptors. The neurotransmitter-powered receptors resemble the coin slots in an arcade game.
Dopamine molecules that enter the slot stimulate the neuron, and the ensuing signaling cascades. Two machines with variously sized slots represent the D1 and D2 carrying neurons. The correct size of antipsychotic medication molecules can block D2 receptor slots but not D1 receptors.
As a result, it was believed that the secret to these medications' efficacy in treating schizophrenia symptoms was their effect on D2 receptors. The researchers achieved this finding by utilizing an imaging-based experiment that employed miniature microscopes to view how various medicines affected dopamine-expressing neurons in the mouse brain in real time.
According to Parker, the results disproved the fundamental idea about how antipsychotics operate and indicated that future research would need to reevaluate the mechanisms by which antipsychotics function to account for the impact of D1 receptor regulation.
Parker concludes: "Our study exposed our lack of understanding for how these drugs work and uncovered new therapeutic strategies for developing more effective antipsychotics."
- Nature Neuroscience. Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neuronsAntipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons.
- Centre for Addiction and Mental Health. Antipsychotic Medications.
- WHO. Schizophrenia.